Cell and Gene Therapy

Description
Text

The Cell and Gene Therapy Working Group was established in 2023 through the merger of the Cell Therapy Working Group and Gene Therapy Working Group. This regulator-only working group allows for the discussion of topics where regulatory policy is under development, with a focus on convergence of regulatory approaches within the confines of national regulations for advanced therapies.

Title
Members
Widgets
Title
Members
Widgets
Text
  • ANMAT, Argentina
  • ANVISA, Brazil
  • COFEPRIS, Mexico
  • CPED, Israel
  • EDA, Egypt
  • EMA, European Commission
  • FDA, United States
  • HC, Canada
  • HSA, Singapore
  • ISPCH, Chile
  • MHLW/PMDA, Japan
  • MFDS, Republic of Korea
  • MHRA, United Kingdom
  • MOH, Indonesia
  • NPRA, Malaysia
  • SAPHRA, South Africa
  • SFDA, Saudi Arabia
  • Swissmedic, Switzerland
  • TGA, Australia
  • TFDA, Chinese Taipei
  • Thai FDA, Thailand
  • TITCK, Türkiye

Observers:

  • PAHO/PANDRA
  • WHO
Title
Scope (Mandate) and Objectives
Widgets
Title
Scope (Mandate) and Objectives
Widgets
Text

The Cell and Gene Therapy Working Group is a regulator-only working group with the following objectives: 

 

  1. Provide an open forum for discussion of cell and gene therapy products.

     

  2. Retain knowledge of regulatory activities in participating regions

     

  3. Identify Topics for regulatory convergence or harmonization.

     

  4. When appropriate, propose topics to ICH for harmonisation  

     

Products under discussion:

 

  • Cell therapy products:
    • Gene-modified cells
    • Viral vectors
    • Oncolytic vectors
    • Genetically modified bacterial vector-based gene therapy products
    • Genome editing technologies
    • Tissue engineered products
    • Xenotransplantation products 


 

Key Deliverables:

  • Post results of working group projects

  • Draft reflection papers on topics with potential for convergence or harmonization

  • Publish journal articles and white papers, when appropriate

  • Update information on the regulatory landscape of cell and gene therapy products (Framework Project) 

Title
Work in Progress
Widgets
Title
Work in Progress
Widgets
Text

The working group has an on-going project, “Framework Project” which consists of a list of regulations, guidance documents, reflection papers and guidelines, and a list of approved products in participating regions. This project will be updated as needed and is considered a living document.

Promoted To List
On
Date